BioCentury
ARTICLE | Finance

LSP checks in

Why LSP made its first investment in checkpoint inhibitor space via ImCheck

May 5, 2017 9:37 PM UTC

ImCheck Therapeutics S.A.S.’s focus on checkpoint receptors that are expressed on a subset of T cells that are different from the cellular targets of other checkpoint modulators convinced LSP to make its first immuno-oncology investment.

The VC participated in ImCheck’s €20 million ($21.8 million) series A round announced last week. Boehringer Ingelheim Venture Fund, Kurma Partners and Idinvest led the round. Gimv also participated. ...